trial

A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

NCTId NCT07459647
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Recruiting
Enrollment 500 (estimated)
Sponsored by MapLight Therapeutics
Primary completion 2030-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Recruiting
Enrollment
500 (estimated)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2026-03-31
Primary completion
2030-02
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
ML-007C-MA

Sponsors

MapLight TherapeuticsLead Sponsor

Investigators

1
MapLight TherapeuticsStudy Director

Sites

5 total
Lemon Grove, United StatesMiami Lakes, United StatesChicago, United StatesStaten Island, United StatesDeSoto, United States

Linked catalysts

1
A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia — primary completion2030-02

Facts & assertions

4 sourced
Enrollment
500
Phase
PHASE2
Primary Completion Date
2030-02
Status
RECRUITING
relationships
The graph out of here
drug
ML-007C-MA
drug
lead_sponsor
MapLight Therapeutics
company
indication
Central Nervous System Diseases
indication
Psychotic Disorders
indication
Schizophrenia
indication
investigator
MapLight Therapeutics
person